tsh biopharmoration Ltd (TWO:8432) — Market Cap & Net Worth
Market Cap & Net Worth: tsh biopharmoration Ltd (8432)
tsh biopharmoration Ltd (TWO:8432) has a market capitalization of $61.58 Million (NT$1.95 Billion) as of June 17, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #21155 globally and #1299 in its home market, demonstrating a -3.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying tsh biopharmoration Ltd's stock price NT$50.90 by its total outstanding shares 38398000 (38.40 Million). Review 8432 current and long-term liabilities to assess the company's total debt and financial obligations.
tsh biopharmoration Ltd Market Cap History: 2015 to 2026
tsh biopharmoration Ltd's market capitalization history from 2015 to 2026. Data shows growth from $69.99 Million to $61.58 Million (2.98% CAGR).
tsh biopharmoration Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how tsh biopharmoration Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.07x
tsh biopharmoration Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.66x
tsh biopharmoration Ltd's market cap is 0.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $58.85 Million | $486.28 Million | $64.97 Million | 0.12x | 0.91x |
| 2018 | $74.44 Million | $515.65 Million | $57.78 Million | 0.14x | 1.29x |
| 2019 | $82.28 Million | $507.67 Million | $85.33 Million | 0.16x | 0.96x |
| 2020 | $63.42 Million | $447.86 Million | $61.57 Million | 0.14x | 1.03x |
| 2021 | $50.14 Million | $413.48 Million | $47.11 Million | 0.12x | 1.06x |
| 2022 | $55.52 Million | $741.07 Million | $61.89 Million | 0.07x | 0.90x |
| 2023 | $60.85 Million | $810.92 Million | $61.99 Million | 0.08x | 0.98x |
| 2024 | $74.16 Million | $1.12 Billion | $113.09 Million | 0.07x | 0.66x |
Competitor Companies of 8432 by Market Capitalization
Companies near tsh biopharmoration Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to tsh biopharmoration Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
tsh biopharmoration Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, tsh biopharmoration Ltd's market cap moved from $69.99 Million to $ 61.58 Million, with a yearly change of 2.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$61.58 Million | -12.99% |
| 2025 | NT$70.77 Million | -4.57% |
| 2024 | NT$74.16 Million | +21.87% |
| 2023 | NT$60.85 Million | +9.60% |
| 2022 | NT$55.52 Million | +10.73% |
| 2021 | NT$50.14 Million | -20.93% |
| 2020 | NT$63.42 Million | -22.92% |
| 2019 | NT$82.28 Million | +10.52% |
| 2018 | NT$74.44 Million | +26.50% |
| 2017 | NT$58.85 Million | -14.87% |
| 2016 | NT$69.14 Million | -1.22% |
| 2015 | NT$69.99 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of tsh biopharmoration Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.58 Million USD |
| MoneyControl | $61.58 Million USD |
| MarketWatch | $61.58 Million USD |
| marketcap.company | $61.58 Million USD |
| Reuters | $61.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more